GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Woojung Bio Inc (XKRX:215380) » Definitions » Capex-to-Operating-Cash-Flow

Woojung Bio (XKRX:215380) Capex-to-Operating-Cash-Flow : 0.09 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Woojung Bio Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Woojung Bio's Capital Expenditure for the three months ended in Dec. 2023 was ₩-400.14 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was ₩4,576.45 Mil.

Hence, Woojung Bio's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2023 was 0.09.


Woojung Bio Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Woojung Bio's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Woojung Bio Capex-to-Operating-Cash-Flow Chart

Woojung Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only 11.47 - 21.25 4.60 -

Woojung Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 - - - 0.09

Competitive Comparison of Woojung Bio's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Woojung Bio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Woojung Bio's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Woojung Bio's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Woojung Bio's Capex-to-Operating-Cash-Flow falls into.



Woojung Bio Capex-to-Operating-Cash-Flow Calculation

Woojung Bio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-887.468) / -3222.019
=N/A

Woojung Bio's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-400.135) / 4576.446
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Woojung Bio  (XKRX:215380) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Woojung Bio Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Woojung Bio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Woojung Bio (XKRX:215380) Business Description

Traded in Other Exchanges
N/A
Address
Gwanggyo-ro 145, B-dong 3rd Floor, Next Generation Convergence Technology Research Center, Gyeonggi-do, Yeongtong-gu, Suwon-si, KOR
Woojung Bio Inc is engaged in the research and development of natural science and engineering. Its products include Gene Delivery, Antibody Production, Immunodeficiency model, Human-to-human model, Zika, Mers, Dengue, Influenza Virus Research, Influenza virus, vaccine studies, and Elegant Goettingen Mini Pig.

Woojung Bio (XKRX:215380) Headlines

No Headlines